Edition:
United Kingdom

Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

13.73USD
18 Jun 2018
Change (% chg)

$2.66 (+24.03%)
Prev Close
$11.07
Open
$11.68
Day's High
$14.00
Day's Low
$11.45
Volume
1,302,788
Avg. Vol
411,384
52-wk High
$14.00
52-wk Low
$1.48

Chart for

About

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of... (more)

Overall

Beta: 1.91
Market Cap(Mil.): $317.78
Shares Outstanding(Mil.): 74.77
Dividend: --
Yield (%): --

Financials

  ARWR.OQ Industry Sector
P/E (TTM): -- 84.11 32.75
EPS (TTM): -0.67 -- --
ROI: -55.08 1.56 14.38
ROE: -61.13 2.43 16.07

BRIEF-Arrowhead Pharmaceuticals Presents Preclinical Data On Expanding Cardiometabolic Pipeline

* ARROWHEAD PHARMACEUTICALS PRESENTS PRECLINICAL DATA ON EXPANDING CARDIOMETABOLIC PIPELINE

11 May 2018

BRIEF-Arrowhead Pharmaceuticals Reports Qtrly Loss Per Share $0.18

* ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2018 SECOND QUARTER RESULTS

08 May 2018

BRIEF-Arrowhead Pharmaceuticals Arrowhead Begins Dosing In Phase 1/2 Study Of ARO-HBV

* ARROWHEAD BEGINS DOSING IN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF CHRONIC HEPATITIS B Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

27 Mar 2018

BRIEF-Arrowhead Begins Dosing In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

* ARROWHEAD BEGINS DOSING IN PHASE 1 STUDY OF ARO-AAT FOR TREATMENT OF ALPHA-1 LIVER DISEASE Source text for Eikon: Further company coverage:

12 Mar 2018

BRIEF-Arrowhead Receives Regulatory Clearance To Begin Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

* ARROWHEAD RECEIVES REGULATORY CLEARANCE TO BEGIN PHASE 1 STUDY OF ARO-AAT FOR TREATMENT OF ALPHA-1 LIVER DISEASE

22 Feb 2018

BRIEF-Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-AAT

* ARROWHEAD PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FOR ARO-AAT

15 Feb 2018

BRIEF-Arrowhead Receives Regulatory Clearance To Begin Phase 1/2 Study Of Aro-Hbv For Treatment Of Hepatitis B

* ARROWHEAD RECEIVES REGULATORY CLEARANCE TO BEGIN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF HEPATITIS B Source text for Eikon: Further company coverage:

15 Feb 2018

BRIEF-Arrowhead Pharmaceuticals Reports Fiscal 2018 Q1 Results

* ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2018 FIRST QUARTER RESULTS

09 Feb 2018

BRIEF-Arrowhead Pharmaceuticals Announces Pricing Of Underwritten Public Offering Of Common Stock

* ARROWHEAD PHARMACEUTICALS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

18 Jan 2018

BRIEF-Arrowhead Pharma Announces Proposed Underwritten Offering Of Common Stock

* ARROWHEAD PHARMACEUTICALS ANNOUNCES PROPOSED UNDERWRITTEN OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

17 Jan 2018

Earnings vs. Estimates